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The issue of the legitimate therapeutic potential associated with
patient participation as research subjects in phase 1 antineoplastic
clinical trials has generated considerable, and often quite
contentious, debate.
Some have strongly argued the chances that clinical benefit will
be attained by patients entered into these studies are so remote
that individuals who believe, and physicians who suggest, such an
outcome is a realistic goal are suffering from what has been
described as a therapeutic misconception (Appelbaum et al, 1987;
Miller, 2000). Furthermore, it is apparently felt by a group of these
commentators that major efforts are required to be certain that
this ‘misconception’ is dispelled before a cancer patient is
permitted to enter a phase 1 oncology trial. In support of their
contention, several authors have quoted older literature that
revealed that objective response rates of o5–6% are associated
with phase 1 antineoplastic drug studies (Estey et al, 1986;
Decoster et al, 1990; Von Hoff and Turner, 1991; Itoh et al, 1994).
In addition, it has been noted that serious toxic effects were not
rare events in these early experiences in cancer drug development.
However, more recent data published in the peer-reviewed
literature provide a far different picture regarding the potential for
clinical benefit associated with current phase 1 trials in the
oncology arena. For example, Horstmann et al (2005) analysed
the outcome of almost 12000 individuals who participated in 460
phase 1 trials supported by the National Cancer Institute
(Bethesda, MD, USA). Overall, 10.6% of patients experienced an
objective response, which increased to 17.8% when one drug
included in the phase 1 regimen had previously been approved for
some clinical indication by the United States Food and Drug
Administration. These results are quite comparable to that
anticipated for many current programmes routinely utilised as
‘standard-of-care’ in the treatment of advanced and metastatic
malignancies.
Furthermore, it is critical to acknowledge that the potential for
achieving truly substantial clinical benefit through participation in
a phase 1 oncology study, while certainly not a common outcome
at present, is also not beyond quite realistic hope. Note, for
example, that 53 out of 54 chronic myelogenous leukaemia patients
treated on a phase 1 trial of imatinib mesylate achieved a complete
haematologic response (Druker et al, 2001), and that 75% of the
women with advanced ovarian cancer who participated in a phase
1 trial of paclitaxel plus carboplatin attained a major objective
response to this (at that time) novel combination chemotherapy
regimen (Bookman et al, 1996).
In this issue of the British Journal of Cancer, Arkenau et al
(2008), while describing an 18 months long experience with phase
1 trials at the Royal Marsden Hospital (29 studies involving 212
patients), have added highly relevant data that provide important
support to the argument that patient participation as research
subjects in phase 1 oncology trials is associated with the reasonable
potential for clinical benefit.
Overall, an objective response rate of 9% was noted in this report,
but when patients with ‘stable disease’ were included within a
rationally defined category of ‘clinical benefit’, more than 50% of
individuals were considered to fall within this grouping 2 months
after initiation of their phase 1 treatment programme (the first time
assessment of tumour status was undertaken). Of considerable
interest, even at 6 months follow-up, is that one-quarter of the entire
population maintained this clinical state. Treatment-related deaths
were rare (0.47%), and less than 15% of patients entered into these
trials had therapy discontinued secondary to excessive toxicity.
As noted by the investigators, defining the ultimate utility of
these specific novel strategies will require the conduct of phase 3
randomised trials. However, the critical point made in this paper is
that there was nothing in the objective outcome data of these early-
phase studies that even remotely suggests that patients who agree
to participate as research subjects do not have the realistic
potential to achieve a genuinely meaningful degree of individual
clinical benefit.
It is also reasonable to speculate, and even anticipate, that as our
understanding of the complex molecular biology of cancer
improves, it will be possible to ‘target’ treatment to particular
patient populations with a high pretreatment probability of
achieving both an objective response and more subjective clinical
benefit from the specific treatment programme (Druker et al,
2001). In addition, as noted by Arkenau et al (2008), the
establishment, and ultimate routine use, of more objective metrics
to select patients for participation in phase 1 trials may result in a
more favourable risk-to-benefit ratio associated with research
subject participation in this group of early-stage cancer drug
development studies.
Based on increasingly solid data, it is reasonable to conclude
that future proclamations of the fundamental absence of *Correspondence: Dr M Markman; E-mail: mmarkman@mdanderson.org
British Journal of Cancer (2008) 98, 1021–1022
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.comtherapeutic intent associated with phase 1 antineoplastic drug
trials simply do not reflect the current reality of cancer drug
development. However, it is also important to acknowledge that
there are particular phase 1 oncology trials that may appropriately
be considered to be purely investigative in intent (eg, study
examining a single very low dose of a cytostatic agent attached to a
novel isotope designed to image distribution of the delivered
material).
Finally, it is this commentator’s hope that future discussions of
the legitimate potential for clinical benefit associated with
participation in early-stage cancer trials will increasingly focus
on the specifics of the study (eg, agents to be employed; prior
knowledge of activity; strength of preclinical data suggesting
utility, etc.) rather than on the simple description of the ‘phase’ of
the trial. It is relevant to note that agreement by clinical
investigators, treating oncologists, various regulatory agencies,
and institutional ethical review boards, regarding this critical issue
may ultimately result in an improvement in the process of
obtaining meaningful informed consent from individuals being
considered for entry into these important studies.
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